<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2312200354
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEFFIX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LAMIVUDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        303.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO OPERATION" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO OPERATION
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1182]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in Zeffix is lamivudine.&nbsp;</p><p><strong>Zeffix is used to treat long term (chronic) hepatitis B infection in adults.</strong></p><p>Zeffix is an antiviral medicine that suppresses the hepatitis B virus and belongs to a group of medicines called <em>nucleoside analogue reverse transcriptase inhibitors (NRTIs)</em>.</p><p>Hepatitis B is a virus which infects the liver, causes long term (chronic) infection, and can lead to liver damage. Zeffix can be used in people whose liver is damaged, but still functions normally (compensated liver disease) and in combination with other medicines in people whose liver is damaged and does not function normally (decompensated liver disease).</p><p>Treatment with Zeffix can reduce the amount of hepatitis B virus in your body. This should lead to a reduction in liver damage and an improvement in your liver function.&nbsp; Not everyone responds to treatment with Zeffix in the same way. Your doctor will monitor the effectiveness of your treatment with regular blood tests.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your healthcare provider should offer you counselling and testing for HIV infection before you start treatment with lamivudine for hepatitis B infection and during treatment. If you have or get HIV infection, see section 3.</p><p><strong>Do not take Zeffix:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re <strong>allergic</strong> to<strong> </strong>lamivudine or to any of the other ingredients of this medicine <em>(listed in Section 6)</em>.</p><p>&egrave; <strong>Check with your doctor</strong> if you think this applies to you.</p><p><strong>Warnings and precautions</strong></p><p>Some people taking Zeffix or other similar medicines are more at risk of serious side effects. You need to be aware of the extra risks:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had other types of <strong>liver disease</strong>, such as hepatitis C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re seriously <strong>overweight</strong> (especially if you&rsquo;re a woman).</p><p>&Uacute;&nbsp; <strong>Talk to your doctor if any of these apply to you</strong>. You may need extra check-ups, including blood tests, while you&rsquo;re taking your medication. <strong>See Section 4 </strong>for more information about the risks.</p><p><strong>Don&rsquo;t stop taking Zeffix </strong>without your doctor&rsquo;s advice, as there is a risk of your hepatitis getting worse. When you stop taking Zeffix your doctor will monitor you for at least four months to check for any problems. This will mean taking blood samples to check for any raised liver enzyme levels, which may indicate liver damage. See section 3 for more information about how to take Zeffix.</p><p><strong>Protect other people</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='color:black'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_42276245-9280-4418-8f8f-0007e898d917 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='color:black'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). Zeffix will not stop you passing hepatitis B infection on to other people. To protect other people from becoming infected with hepatitis B:</p><p>&Yuml;&nbsp; <strong>Use a condom</strong> when you have oral or penetrative sex.</p><p>&Yuml;&nbsp; <strong>Don&rsquo;t risk blood transfer</strong> &mdash; for example, don&rsquo;t share needles.</p><p><strong>Other medicines and Zeffix</strong></p><p>Tell your doctor or pharmacist if you&rsquo;re taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription.</p><p>Remember to tell your doctor or pharmacist if you begin taking a new medicine while you&rsquo;re taking Zeffix.</p><p><strong>These medicines should not be used with Zeffix:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines containing lamivudine, used to treat <strong>HIV infection</strong> (sometimes called the AIDS virus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; emtricitabine used to treat <strong>HIV</strong> or <strong>hepatitis B infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cladribine, used to treat <strong>hairy cell leukaemia</strong></p><p>&egrave;&nbsp;&nbsp; <strong>Tell your doctor</strong> if you&rsquo;re being treated with any of these.<strong> </strong></p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby:</p><p>&egrave;&nbsp;&nbsp; <strong>Talk to your doctor </strong>about the risks and benefits of taking Zeffix during your pregnancy.</p><p>Do not stop treatment with Zeffix without your doctor&rsquo;s advice.</p><p><strong>Breast-feeding </strong></p><p>Zeffix can pass into breast-milk.&nbsp; If you are breast-feeding,<strong> </strong>or thinking about breast-feeding:</p><p>&egrave;&nbsp; <strong>Talk to your doctor </strong>before you take Zeffix.</p><p><strong>Driving and using machines</strong></p><p>Zeffix may make you feel tired, which could affect your ability to drive or use machines.</p><p>&egrave;&nbsp; Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected.</p><p><strong>Zeffix contains sodium</strong></p><p>This medicine contains less than 1<strong>&nbsp;</strong>mmol sodium (23<strong>&nbsp;</strong>mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor has told you to.</strong> Check with your doctor or pharmacist if you&rsquo;re not sure.</p><p>Stay in regular contact with your doctor<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5089d2cc-624d-45c1-9306-a43b89c61667 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Zeffix helps to control your hepatitis B infection. You need to keep taking it every day to control your infection and stop your illness getting worse.</p><p>&egrave; <strong>Keep in touch with your doctor, and don&rsquo;t stop taking Zeffix</strong> without your doctor&rsquo;s advice.</p><p><strong>How much to take<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2a72bf78-353c-4b88-bf50-a97f1955a872 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>The usual dose of Zeffix is one tablet</strong> (100&nbsp;mg lamivudine) <strong>once a day.</strong></p><p>Your doctor may prescribe a lower dose if you have problems with your kidneys. An oral solution of Zeffix is available for people who need a lower than usual dose, or who can&rsquo;t take tablets.</p><p>&egrave; <strong>Talk to your doctor </strong>if this applies to you.<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5982126b-69b9-4f1c-a12f-9e6233b88729 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Patients who also have or may get HIV infection</strong></p><p>If you have or get HIV that is not being treated with medicines while taking lamivudine for the treatment of hepatitis B infection, the HIV virus may develop resistance to certain HIV medicines and become harder to treat. Lamivudine can also be used to treat HIV infection. Talk to your doctor if you have HIV infection. Your doctor may treat you with another medicine that contains a higher dose of lamivudine, usually 150&nbsp;mg twice a day, as the lower dose of 100&nbsp;mg lamivudine is not enough to treat HIV infection.</p><p>If you are planning to change your HIV treatment, discuss this change with your doctor first.</p><p>&egrave; <strong>Talk to your doctor </strong>if this applies to you.<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e75194e2-258e-44b0-8ca6-cd2550d04fc5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='color:black'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Swallow the tablet whole, with some water. Zeffix can be taken with or without food.</p><p><strong>If you take more Zeffix than you should </strong></p><p>If you accidentally take too much Zeffix, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice. If possible, show them the Zeffix pack.</p><p><strong>If you forget to take Zeffix</strong></p><p>If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before. Don&rsquo;t take a double dose to make up for a missed dose.</p><p><strong>Don&rsquo;t stop taking Zeffix</strong></p><p>You must not stop taking Zeffix without consulting your doctor.&nbsp; There is a risk of your hepatitis getting worse<em> (see section 2)</em>. When you stop taking Zeffix your doctor will monitor you for at least four months to check for any problems. This will mean taking blood samples to check for any raised liver enzyme levels, which may indicate liver damage.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Side effects that were commonly reported in Zeffix clinical trials were tiredness, respiratory tract infections, throat discomfort, headache, stomach discomfort and pain, nausea, vomiting and diarrhoea, increases in liver enzymes and enzymes produced in the muscles <em>(see below)</em><em>.</em></p><p><strong>Allergic reaction </strong></p><p>These are rare (may affect up to 1 in 1,000 people). Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp; swelling of eyelids, face or lips</p><p>&middot;&nbsp;&nbsp;&nbsp; difficulty swallowing or breathing</p><p>&egrave;&nbsp;&nbsp; <strong>Contact a doctor immediately</strong> if you get these symptoms. <strong>Stop taking Zeffix</strong>.</p><p><strong>Side effects thought to be caused by Zeffix</strong></p><p><strong>A very common side effect </strong>(these may affect <strong>more than 1 in 10</strong> people) which may show up in blood tests is:</p><ul><li>an increase in the level of some liver enzymes <em>(transaminases)</em>, which may be a sign of inflammation or damage in the liver.</li></ul><p><strong>A common side effect </strong>(these may affect<strong> up to 1 in 10 </strong>people) is:</p><p>&middot;&nbsp;&nbsp;&nbsp; cramps and muscle pains</p><p>&middot;&nbsp;&nbsp;&nbsp; skin rash or &lsquo;hives&rsquo; anywhere on the body</p><p><strong>A common side effect</strong> which may show up in blood tests is:</p><ul><li>an increase in the level of an enzyme produced in the muscles <em>(creatine phosphokinase)</em> which may be a sign that body tissue is damaged.</li></ul><p><strong>A very rare side effect</strong> (these may affect up to 1 in 10,000 people) is:</p><ul><li>lactic acidosis (excess lactic acid in the blood).</li></ul><p><strong>Other side effects</strong></p><p>Other side effects<strong> </strong>have occurred in a very small number of people, but their exact frequency is unknown</p><ul><li>breakdown of muscle tissue</li><li>a worsening of liver disease after Zeffix is stopped or during treatment if the hepatitis B virus becomes resistant to Zeffix. This can be fatal in some people.</li></ul><p>A side effect which may show up in blood tests is:</p><ul><li>a decrease in the number of cells involved in blood clotting <em>(thrombocytopenia)</em>.</li></ul><p>If you get any side effects<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f98fef71-a0f8-40c5-bbbc-547ec81f8f3d \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&egrave;&nbsp;&nbsp; <strong>Talk to your doctor or pharmacist.&nbsp; </strong>This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Don&rsquo;t take this medicine after the expiry date shown on the carton and blister.</p><p>Store below 30&nbsp;&deg;C.</p><p>Do not throw away any medicines in your wastewater or household rubbish. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lamivudine. Each film-coated tablet contains 100&nbsp;mg of lamivudine.</p><p>&nbsp;</p><p>The other ingredients are: microcrystalline cellulose, sodium starch glycolate, magnesium stearate, Hypromellose, titanium dioxide, macrogol 400, polysorbate 80, synthetic yellow and red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Zeffix film-coated tablets are supplied in double foil blisters, laminated with polyvinyl chloride containing 28 tablets.
The tablets are butterscotch coloured, capsule shaped, biconvex and engraved “GX CG5” on one side.


Not all pack-sizes may be available in your country.

ZEFFIX is a trademark owned by or licensed to the GSK group of companies
© 2024 GSK group of companies. All rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p>Delpharm Poznań Sp&oacute;łka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland</p><p><strong>Packed by:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*</p><p>*member of the GSK group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: UK_v19
This leaflet was last revised on: 21 June 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المكوِّن الفعَّال في زيفيكس هو لاميڤودين.&nbsp;</p><p dir="RTL"><strong>يستخدم زيفيكس لعلاج عدوى الالتهاب الكبدي الوبائي &quot;بي&quot; طويل المدى (المزمن) عند البالغين.</strong></p><p dir="RTL">زيفيكس هو دواء مضاد للفيروسات لتثبيط فيروس الالتهاب الكبدي &quot;بي&quot; وينتمي إلى فئة من الأدوية تُسمى <em>الأدوية</em> <em>النيوكليوزيدية المُثبطة ل</em><em>إ</em><em>نزيم المنتسخة المعاكس</em> <em>(NRTI)</em>.</p><p dir="RTL">الالتهاب الكبدي &quot;بي&quot; هو فيروس يصيب الكبد، ويسبب عدوى مزمنة طويلة الأمد، ويمكن أن يؤدي إلى تلف الكبد. يمكن استخدام زيفيكس لعلاج الأشخاص الذين أصيبوا بتلف الكبد، ولكن لا يزال الكبد يعمل بشكل طبيعي (مرض الكبد التعويضي) ويمكن استخدامه بالتزامن مع أدوية أخرى لعلاج الأشخاص الذين أصيبوا بتلف الكبد ولا يعمل الكبد بشكل طبيعي (مرض الكبد غير التعويضي).</p><p dir="RTL">يمكن أن يقلل العلاج باستخدام زيفيكس من مقدار فيروس الالتهاب الكبدي &quot;بي&quot; في جسمك. ومن المفترض أن يؤدي ذلك إلى انخفاض في نسبة تلف الكبد وتحسُّن في وظائف الكبد. وتختلف استجابة المرضى للعلاج بعقار زيفيكس. سوف يتابع طبيبك مدى فعالية العلاج لديك من خلال إجراء فحوصات الدم بشكل دوري.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب على الطبيب الخاص بك إرشادك إلى اجراء اختبار عدوى فيروس نقص المناعة البشرية أثناء العلاج و قبل بدء العلاج بعقار لاميڤودين الخاص بتثبيط عدوى التهاب الكبد الوبائي بي. إذا كنت مصابا بفيروس المناعة البشرية، قم بمراجعة القسم 3.</p><p dir="RTL"><strong>لا تتناول زيفيكس:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> من لاميڤودين أو أي من المكوّنات الأخرى لهذا الدواء <em>(المذكورة في القسم 6)</em>.</p><p dir="RTL">&ccedil;&nbsp; <strong>استشر طبيبك</strong> إذا كنت تعتقد أن هذه الحالة تنطبق عليك.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">بعض المرضى الذين يتناولون زيفيكس أو غيره من الأدوية المماثلة يكونون أكثر عُرضة للإصابة بالآثار الجانبية الخطيرة. يجب أن تضع في اعتبارك المخاطر الأخرى التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق لك، في أي وقت، الإصابة بأنواع أخرى من <strong>أمراض بالكبد</strong>، مثل مرض الالتهاب الكبدي الوبائي &quot;سي&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>البدانة المفرطة</strong> (على الأخص إذا كنتِ امرأة).</p><p dir="RTL">&ccedil;&nbsp; <strong>استشر طبيبك إذا كنت تعاني من أي من الأمراض سالفة الذكر</strong>. قد تحتاج إلى مزيد من الفحوصات، بما في ذلك فحوصات الدم، أثناء تناول العلاج. <strong>انظر القسم 4</strong> لمزيد من المعلومات عن هذه المخاطر.</p><p dir="RTL"><strong>لا تتوقف عن تناول زيفيكس</strong> دون استشارة طبيبك، فهناك خطورة من أن يزداد الالتهاب الكبدي لديك سوءًا. عندما تتوقف عن تناول زيفيكس، سيتابعك طبيبك لمدة أربعة أشهر على الأقل للتأكد من عدم وجود أي مشاكل. وهذا يعني أخذ عينات الدم للتحقق من عدم ارتفاع مستويات أي من إنزيمات الكبد، الأمر الذي قد يشير إلى تلف الكبد. انظر القسم 3 لمزيد من المعلومات حول كيفية تناول زيفيكس.</p><p dir="RTL"><strong>حماية الآخرين</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:12.0pt;
font-family:"Arial",sans-serif;color:black'><span style='mso-element:field-begin'></span>
</span></b><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;
color:black;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span lang=EN-US
style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'><span
dir=RTL></span><span dir=RTL></span> </span></b><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black;mso-bidi-font-weight:
bold'>VAULT_ND_244da5a9-f896-4a96-be00-291436315acc \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'><span
dir=RTL></span><span dir=RTL></span> </span></b><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;
color:black'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:12.0pt;
font-family:"Arial",sans-serif;color:black'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">تنتقل العدوى بالالتهاب الكبدي &quot;بي&quot; من خلال الاتصال الجنسي مع شخص مصاب بالمرض أو من خلال نقل دم ملوث (على سبيل المثال، استخدام عدة أشخاص لإبر الحقن نفسها). لن يعمل زيفيكس على منع انتقال عدوى الالتهاب الكبدي &quot;بي&quot; منك لأشخاص آخرين. لحماية الآخرين من الإصابة بالالتهاب الكبدي &quot;بي&quot;:</p><p dir="RTL">&Yuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استخدم الواقي الذكري </strong>أثناء ممارسة الجنس الفموي أو الإيلاج.</p><p dir="RTL">&Yuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تخاطر بنقل الدم </strong>&mdash; على سبيل المثال، لا تستخدم إبر الحقن نفسها مع آخرين.</p><p dir="RTL"><strong>الأدوية الأخرى وزيفيكس</strong></p><p dir="RTL">قم بإبلاغ طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى، أو تناولت أي أدوية أخرى مؤخرًا، أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تحتوي على أعشاب، أو الأدوية التي يمكن شراؤها دون وصفة طبية.</p><p dir="RTL">تذكر إبلاغ طبيبك أو الصيدلي في حالة بدء تناول دواء جديد أثناء تناولك لزيفيكس.</p><p dir="RTL"><strong>لا يمكن تناول الأدوية التالية مع زيفيكس:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية (السائلة عادةً) التي تحتوي على السوربيتول أو غيره من الكحولات السكرية (مثل زيليتول أو مانيتول أو لاكتيتول أو مالتيتول)، إذا كان تناولها يتم بشكل منتظم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تحتوي على لاميڤودين، المستخدم في علاج <strong>عدوى فيروس نقص المناعة البشرية</strong> (يُطلق عليه أحيانًا فيروس الإيدز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمتريسيتابين الذي يتم استخدامه في علاج <strong>عدوى فيروس نقص المناعة البشرية</strong> أو <strong>عدوى الالتهاب الكبدي &quot;بي&quot;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلادريبين، المستخدم في علاج<strong> الابيضاض المُشعر الخلايا</strong></p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>&nbsp;أخبر طبيبك</strong> إذا كنت تُعالج بأي من هذه الأدوية.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا &rlm;‫كنتِ حاملاً أو تظنين أنكِ حامل أو إذا كنتِ تخططين للإنجاب:</p><p dir="RTL"><strong>&ccedil;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تحدثي مع طبيِبك</strong> حول مخاطر ومنافع تناول زيفيكس أثناء الحمل.</p><p dir="RTL">لا تتوقفي عن العلاج بزيفيكس دون استشارة طبيبك.</p><p dir="RTL"><strong>الرضاعة الطبيعية </strong></p><p dir="RTL">يمكن أن ينتقل زيفيكس للطفل من خلال لبن الأم. إذا كنتِ ترضعين طفلكِ رضاعة طبيعية أو تفكرين في ذلك:</p><p dir="RTL">&ccedil;&nbsp; <strong>&nbsp;&nbsp;&nbsp;ينبغي استشارة طبيبكِ</strong> قبل تناول زيفيكس.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يتسبب زيفيكس في شعورك بالتعب، مما قد يؤثر على قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&ccedil;&nbsp; &nbsp;&nbsp;&nbsp;تجنب القيادة أو استخدام الآلات إذا لم تكن متأكدًا من عدم تأثرك.</p><p dir="RTL"><strong>زيفيكس يحتوى على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من واحد ملي مول من الصوديوم (23 ملجم) لكل قرص، مما يعني أنه في الأساس &quot;خالي من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب دائمًا</strong><strong> الالتزام بتعليمات طبيبك بدقة فيما يتعلق بطريقة تناول هذا الدواء.</strong> ويجب استشارة طبيبك أو الصيدلي في حالة الشك بشأن طريقة استعمالها على الوجه الصحيح.</p><p>تواصل بانتظام مع طبيبك<!--[if supportFields]><span lang=AR-SA
style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
</span><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;
font-weight:normal;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;
mso-ansi-font-weight:normal;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-US dir=LTR style='font-size:12.0pt;
font-family:"Arial",sans-serif;font-weight:normal;mso-bidi-font-weight:bold'>VAULT_ND_cad17523-e0ce-49a4-a7d8-203d36a9a701
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">يساعد زيفيكس في التحكم في عدوى الالتهاب الكبدي &quot;بي&quot;. ويجب عليك تناوله يوميًا للسيطرة على العدوى ومنع تفاقم المرض.</p><p dir="RTL">&ccedil;&nbsp; <strong>ابق على اتصال بطبيبك ولا تتوقف عن تناول زيفيكس </strong>بدون مشورته.</p><p><strong>الجرعة<!--[if supportFields]><span lang=AR-SA style='font-size:
12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:normal;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> </span><span lang=EN-US
dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;font-weight:
normal;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;
mso-ansi-font-weight:normal;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-US dir=LTR style='font-size:12.0pt;
font-family:"Arial",sans-serif;font-weight:normal;mso-bidi-font-weight:bold'>VAULT_ND_279adf60-1f65-4bd9-817b-8e3918d279e2
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>الجرعة المعتادة من زيفيكس هي قرص واحد</strong> (100 ملجم من لاميڤودين) <strong>مرة واحدة يوميًا.</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكليتين، قد يقلل طبيبك الجرعة الموصوفة لك. يتوفر محلول للإعطاء عن طريق الفم للأشخاص الذين يحتاجون إلى جرعة أقل من المعتاد، أو الذين لا يستطيعون تناول الأقراص.</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى الطبيب</strong> إذا كانت هذه الحالة تنطبق عليك.<!--[if supportFields]><span lang=AR-SA
style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'><span
style='mso-element:field-begin'></span> </span><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-US style='font-size:12.0pt;
font-family:"Arial",sans-serif;color:black'><span dir=RTL></span><span dir=RTL></span>
</span><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;
color:black'>VAULT_ND_d9c17421-7ba7-4751-9ade-605c3c2dadff \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-US style='font-size:12.0pt;
font-family:"Arial",sans-serif;color:black'><span dir=RTL></span><span dir=RTL></span>
</span><span lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;
color:black'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL"><strong>المرضى أو مَن مِن المحتمل اصابتهم بعدوى فيروس نقص المناعة البشرية </strong></p><p dir="RTL">إذا كنت مصابًا بعدوى فيروس نقص المناعة البشرية الذي لا يتم علاجه بالأدوية أثناء تناول عقار لاميڤودين، فقد يبني الفيروس أجسام مضادة لبعض أدوية فيروس نقص المناعة البشرية ويصبح علاجه أكثر صعوبة. يمكن أيضا استخدام عقار لاميڤودين لعلاج عدوى فيروس نقص المناعة البشرية. إذا كنت مصابا بفيروس نقص المناعة البشرية، استشر الطبيب. قد يعالجك طبيبك بدواء آخر يحتوي على جرعة أعلى من مادة لاميڤودين، عادة 150 ملجم مرتين يوميًا، حيث أن الجرعة الأقل من لاميڤودين 100 ملجم لا تكفي لعلاج عدوى فيروس نقص المناعة البشرية. إذا كنت تخطط لتغيير علاج فيروس نقص المناعة البشرية الذي تتناوله، ناقش هذا التغيير مع طبيبك أولاً.</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى الطبيب</strong> إذا كانت هذه الحالة تنطبق عليك.<!--[if supportFields]><span lang=AR-SA
style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'><span
style='mso-element:field-begin'></span> </span><span lang=EN-US dir=LTR
style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-US style='font-size:12.0pt;
font-family:"Arial",sans-serif;color:black'><span dir=RTL></span><span dir=RTL></span>
</span><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;
color:black'>VAULT_ND_d3169906-b1bd-4bcb-b12d-2dfa99a6e32b \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-US style='font-size:12.0pt;
font-family:"Arial",sans-serif;color:black'><span dir=RTL></span><span dir=RTL></span>
</span><span lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;
color:black'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;color:black'><span
style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">ابتلع القرص كاملاً، مع شرب بعض من الماء. يمكن تناول زيفيكس مع الطعام أو بدونه.</p><p dir="RTL"><strong>في حالة تناول جرعة زيفيكس زائدة عما ينبغي تناوله </strong></p><p dir="RTL">في حالة تناول جرعة زائدة من زيفيكس دون قصد، اتصل بطبيبك أو الصيدلي، أو توجه إلى قسم الطوارئ بأقرب مستشفى للحصول على الاستشارة الإضافية. لو أمكن، أظهر عبوة زيفيكس.</p><p dir="RTL"><strong>في حالة نسيان تناول زيفيكس</strong></p><p dir="RTL">في حالة نسيان تناول الجرعة، يجب تناولها فور تذكرها. ثم أكمل العلاج كما في السابق. لا تتناول جرعة مضاعفة لتعويض الجرعة التي فاتتك.</p><p dir="RTL"><strong>لا تتوقف عن تناول زيفيكس</strong></p><p dir="RTL">يجب ألا تتوقف عن تناول زيفيكس دون استشارة طبيبك. فهناك خطورة من أن يزداد الالتهاب الكبدي لديك سوءًا <em>(انظر القسم 2)</em>. عندما تتوقف عن تناول زيفيكس، سيتابعك طبيبك لمدة أربعة أشهر على الأقل للتأكد من عدم وجود أي مشاكل. وهذا يعني أخذ عينات الدم للتحقق من عدم ارتفاع مستويات أي من إنزيمات الكبد، الأمر الذي قد يشير إلى تلف الكبد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء، مثل جميع الأدوية، في حدوث آثار جانبية، ولكن ليس بالضرورة أن يصاب بها جميع الأشخاص.</p><p dir="RTL">كانت الآثار الجانبية التي تم الإبلاغ عنها بشكل شائع في التجارب السريرية التي أجريت على زيفيكس هي التعب، وعدوى الجهاز التنفسي، وعدم الراحة في الحلق، والصداع، واضطراب المعدة والألم والغثيان والقيء والإسهال، وزيادة في إنزيمات الكبد والإنزيمات التي يتم إنتاجها في العضلات <em>(انظر أدناه)</em>.</p><p dir="RTL"><strong>الحساسية </strong></p><p dir="RTL">نادرة الحدوث (قد تصيب حتى شخص واحد من كل 1000 شخص). تشمل العلامات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تورّم الجفون أو الوجه، أو الشفتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صعوبة في البلع أو التنفس</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>استشر الطبيب على الفور</strong> إذا أصابتك هذه الأعراض. <strong>توقف عن تناول زيفيكس</strong>.</p><p dir="RTL"><strong>الآثار الجانبية التي يُعتقد أن يتسبب فيها زيفيكس </strong></p><p dir="RTL"><strong>هناك أثر جانبي شائع جدًا</strong> (قد يؤثر على <strong>أكثر من شخص بين كل 10</strong>&nbsp;أشخاص) وقد يظهر في فحوصات الدم، وهو:</p><ul><li dir="RTL">زيادة في مستوى بعض إنزيمات الكبد <em>(ناقلات الأمين)</em>، والتي قد تكون علامة على وجود التهاب أو تلف في الكبد.</li></ul><p dir="RTL"><strong>من الآثار الجانبية الشائعة</strong> (التي يمكن أن تصيب <strong>حتى شخص واحد من بين كل 10</strong> أشخاص)، وهو:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تشنجات وآلام في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; طفح جلدي أو شرى في أي مكان على الجسم</p><p dir="RTL"><strong>هناك أثر جانبي شائع</strong> قد يظهر في فحوصات الدم، وهو:</p><ul><li dir="RTL">زيادة في مستوى إنزيم يتم إنتاجه في العضلات <em>(فسفوكيناز الكرياتين)</em>، والذي قد يكون علامة على تلف أنسجة الجسم.</li></ul><p dir="RTL"><strong>هناك أثر جانبي نادر جدًا</strong> (يمكن أن يصيب حتى شخص واحد من بين كل 10000 شخص)، وهو:</p><ul><li dir="RTL">حُماض لاكتيكي (مستويات زائدة من حمض اللاكتيك في الدم).</li></ul><p dir="RTL"><strong>آثار جانبية أخرى </strong></p><p dir="RTL">حدثت آثار جانبية أخرى لدى عدد قليل جدًا من الأشخاص ولكن معدل تكرارها الدقيق غير معروف</p><ul><li dir="RTL">تمزق في الأنسجة العضلية</li><li dir="RTL">تفاقم مرض الكبد بعد التوقف عن تناول زيفيكس أو أثناء العلاج إذا أصبح فيروس الالتهاب الكبدي &quot;بي&quot; مقاومًا لزيفيكس. وقد يكون هذا العرض مميتًا لدى بعض الأشخاص.</li></ul><p dir="RTL">هناك أثر جانبي قد يظهر في فحوصات الدم، وهو:</p><ul><li dir="RTL">انخفاض في عدد الخلايا المشاركة في تجلط الدم <em>(نقص الصفائح الدموية)</em>.</li></ul><p><strong>في حالة الإصابة بالآثار الجانبية<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
</span><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;
font-weight:normal;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;
mso-ansi-font-weight:normal;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=EN-US dir=LTR style='font-size:12.0pt;
font-family:"Arial",sans-serif;font-weight:normal;mso-bidi-font-weight:bold'>VAULT_ND_b6e25612-1ac9-4315-87e5-26d74bad1b1b
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-US style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ansi-font-weight:
normal;mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>استشر طبيبك أو الصيدلي.</strong> وهذا يتضمن أي أعراض جانبية محتملة غير واردة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تتناول هذا الدواء بعد انقضاء تاريخ الصلاحية المدون على العبوة الكرتون والشريط الفقاعي.</p><p dir="RTL">يخزن في درجة حرارة أقل من 30&deg; م.</p><p dir="RTL">لا تتخلص من الأدوية في الفضلات السائلة ولا المخلفات المنزلية. استشر الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. من شأن هذه الإجراءات أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة بهذا الدواء هي لاميڤودين. يحتوي كل قرص مكسو بغلاف غشائي على 100 ملجم من لاميڤودين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سليلوز دقيق التبلور، جلايكولات نشاء الصوديوم، سترات الماغنيسيوم، هيبروميلوس، ثاني أكسيد التيتانيوم، ماكروغول 400، بولسوربيت 80، أكسيد الحديد الأصفر والأحمر الاصطناعي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص زيفكس المكسوة بغلاف غشائي على هيئة شرائط فقاعية ذات طبقة مزدوجة من رقائق الألومنيوم، مغلفة بالبولي فينيل كلوريد غير الشفاف في عبوات كرتون تحتوي على 28 قرصًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص برتقالية داكنة اللون على شكل كبسولة محدبة من الجانبين ومنقوش على أحد جانبيها &quot;GX CG5&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في دولتك.</p><p dir="RTL"><em>زيفيكس&nbsp;</em>علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2024 مجموعة شركات جلاكسو سميث كلاين. جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">ديلفارم بوزنان أسبولكا أكسيجنا، أولي. جرانڤالسكا 189، 60 - 322 بوزنان، بولندا</p><p dir="RTL"><strong>تعبئة:</strong></p><p dir="RTL">*جلاكسو العربية السعودية المحدودة* جدة، السعودية</p><p dir="RTL"><strong>مالك التسويق المعتمد:</strong></p><p dir="RTL">جلاكسو العربیة السعودية المحدودة* جدة، السعودية</p><p dir="RTL">*عضو مجموعة شركات جلاكسوسميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: UK_v19
تمت آخر مراجعة لهذه النشرة في 21 يونيو 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zeffix 100 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 100 mg lamivudine

For the full list of excipients see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

Butterscotch coloured, film-coated, capsule shaped, biconvex tablet, engraved “GX CG5” on one face.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zeffix is indicated for the treatment of chronic hepatitis B in adults with:</p><p>&nbsp;</p><p>&sect;&nbsp; compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see section 5.1).</p><p>&nbsp;</p><p>&sect;&nbsp; decompensated liver disease in combination with a second agent without cross-resistance to lamivudine (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy with Zeffix should be initiated by a physician experienced in the management of chronic hepatitis B.</p><p>&nbsp;</p><p><u>Posology</u></p><p><em>Adults</em></p><p>The recommended dosage of Zeffix is 100&nbsp;mg once daily.&nbsp;</p><p>In patients with decompensated liver disease, lamivudine should always be used in combination with a second agent, without cross-resistance to lamivudine, to reduce the risk of resistance and to achieve rapid viral suppression.&nbsp;</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>The optimal duration of treatment is unknown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see&nbsp;section&nbsp;4.4). Serum ALT and HBV&nbsp;DNA levels should be followed regularly after treatment discontinuation to detect any late virological relapse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs&nbsp;seroconversion or there is evidence of loss of efficacy. With prolonged treatment, regular reassessment is recommended to confirm that continuation of the selected therapy remains appropriate for the patient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with decompensated liver disease or cirrhosis and in liver transplant recipients, treatment cessation is not recommended (see section 5.1).</p><p>If lamivudine is discontinued, patients should be periodically monitored for evidence of recurrent hepatitis (see section 4.4).</p><p>&nbsp;</p><p><em>Clinical resistance</em></p><p>In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels.&nbsp; In order to reduce the risk of resistance in patients receiving lamivudine monotherapy, a switch to or addition of an alternative agent without cross-resistance to lamivudine based on therapeutic guidelines should be considered if serum HBV DNA remains detectable at or beyond 24 weeks of treatment (see section 5.1).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance. The dosage should, therefore, be reduced for patients with a creatinine clearance of &lt;&nbsp;50&nbsp;ml/minute. When doses below 100&nbsp;mg are required Zeffix oral solution should be used (see Table 1 below).</p><p>Table 1: Dosage of Zeffix in patients with decreased renal clearance.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Creatinine clearance</strong></p><p><strong>ml/min</strong></p></td><td><p><strong>First dose of Zeffix</strong></p><p><strong>oral solution *</strong></p></td><td><p><strong>Maintenance dose</strong></p><p><strong>once daily</strong></p></td></tr><tr><td><p><strong>30 to &lt;&nbsp;50</strong></p></td><td><p>20&nbsp;ml (100&nbsp;mg)</p></td><td><p>10&nbsp;ml (50&nbsp;mg)</p></td></tr><tr><td><p><strong>15 to &lt;&nbsp;30</strong></p></td><td><p>20&nbsp;ml (100&nbsp;mg)</p></td><td><p>5&nbsp;ml (25&nbsp;mg)</p></td></tr><tr><td><p><strong>5 to &lt;&nbsp;15</strong></p></td><td><p>7&nbsp;ml (35&nbsp;mg)</p></td><td><p>3&nbsp;ml (15&nbsp;mg)</p></td></tr><tr><td><p><strong>&lt;&nbsp;5</strong></p></td><td><p>7&nbsp;ml (35&nbsp;mg)</p></td><td><p>2&nbsp;ml (10&nbsp;mg)</p></td></tr></tbody></table><p>* Zeffix oral solution containing 5&nbsp;mg/ml lamivudine.</p><p>&nbsp;</p><p>Data available in patients undergoing intermittent haemodialysis (for less than or equal to 4&nbsp;hrs dialysis 2-3 times weekly), indicate that following the initial dosage reduction of lamivudine to correct for the patient&rsquo;s creatinine clearance, no further dosage adjustments are required while undergoing dialysis.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>Data obtained in patients with hepatic impairment, including those with end-stage liver disease awaiting transplant, show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction. Based on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.</p><p><em>HIV co‑infection</em></p><p>For the treatment of patients who are co‑infected with HIV and are currently receiving or plan to receive combined antiretroviral treatment including lamivudine, the dose of lamivudine prescribed for HIV infection (usually 150&nbsp;mg/twice daily in combination with other antiretrovirals) should be used.</p><p><em>Elderly</em></p><p>In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of &lt; 50 ml/min.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Zeffix in infants, children and adolescents aged below 18 years have not been established.&nbsp; Currently available data are described in sections 4.4 and 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Oral use.</p><p>Zeffix can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Exacerbations of hepatitis</u></p><p><em>Exacerbations on treatment</em></p><p>Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT.&nbsp; After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline. In patients with compensated liver disease, these increases in serum ALT were generally not accompanied by an increase in serum bilirubin concentrations or signs of hepatic decompensation.</p><p>HBV viral subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have been identified with extended therapy. In some patients the development of YMDD mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT elevations and re-emergence of HBV DNA (see section 4.2). In patients who have YMDD mutant HBV, a switch to or addition of an alternative agent without cross resistance to lamivudine based on therapeutic guidelines should be considered (see section 5.1).</p><p>&nbsp;</p><p><em>Exacerbations after treatment discontinuation</em></p><p>Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA.&nbsp; In the controlled Phase III trials with no-active-treatment follow-up, the incidence of post-treatment ALT elevations (more than 3 times baseline) was higher in lamivudine-treated patients (21%) compared with those receiving placebo (8%).&nbsp; However, the proportion of patients who had post-treatment elevations associated with bilirubin elevations was low and similar in both treatment arms (see Table 3 in section 5.1).&nbsp; For lamivudine-treated patients, the majority of post-treatment ALT elevations occurred between 8 and 12 weeks post-treatment.&nbsp; Most events have been self-limiting, however some fatalities have been observed.&nbsp; If Zeffix is discontinued, patients should be periodically monitored both clinically and by assessment of serum liver function tests (ALT and bilirubin levels), for at least four months, and then as clinically indicated.</p><p>&nbsp;</p><p><em>Exacerbations in patients with decompensated cirrhosis</em></p><p>Transplantation recipients and patients with decompensated cirrhosis are at greater risk from active viral replication. Due to the marginal liver function in these patients, hepatitis reactivation at discontinuation of lamivudine or loss of efficacy during treatment may induce severe and even fatal decompensation.&nbsp; These patients should be monitored for clinical, virological and serological parameters associated with hepatitis B, liver and renal function, and antiviral response during treatment (at least every month), and, if treatment is discontinued for any reason, for at least 6 months after treatment. Laboratory parameters to be monitored should include (as a minimum) serum ALT, bilirubin, albumin, blood urea nitrogen, creatinine, and virological status: HBV antigen/antibody, and serum HBV DNA concentrations when possible. Patients experiencing signs of hepatic insufficiency during or post-treatment should be monitored more frequently as appropriate.</p><p>For patients who develop evidence of recurrent hepatitis post-treatment, there are insufficient data on the benefits of re-initiation of lamivudine treatment.</p><p>&nbsp;</p><p><u>Mitochondrial dysfunction</u></p><p>Nucleoside and nucleotide analogues have been demonstrated <em>in vitro</em> and <em>in vivo</em> to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues. The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlipasemia). Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). The neurological disorders might be transient or permanent. Any child exposed <em>in utero</em> to nucleoside and nucleotide analogues, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in cases which have relevant signs or symptoms.</p><p>&nbsp;</p><p><u>Paediatric patients</u></p><p>Lamivudine has been administered to children (2 years and above) and adolescents with compensated chronic hepatitis B. However, due to limitations of the data, the administration of lamivudine to this patient population is not currently recommended (see section 5.1).</p><p>&nbsp;</p><p><u>Delta hepatitis or hepatitis C</u></p><p>The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised.</p><p>&nbsp;</p><p><u>Immunosuppressive treatments</u></p><p>Data are limited on the use of lamivudine in HBeAg negative (pre-core mutant) patients and in those receiving concurrent immunosuppressive regimes, including cancer chemotherapy. Lamivudine should be used with caution in these patients.</p><p>&nbsp;</p><p><u>Monitoring</u></p><p>During treatment with Zeffix patients should be monitored regularly. Serum ALT and HBV DNA levels should be monitored at 3 month intervals and in HBeAg positive patients HBeAg should be assessed every 6 months.</p><p>&nbsp;</p><p><u>HIV co-infection</u></p><p>For the treatment of patients who are co-infected with HIV and are currently receiving or plan to receive treatment with an antiretroviral combination regimen including lamivudine, the dose of lamivudine prescribed for HIV infection (usually 150&nbsp;mg/twice daily in combination with other antiretrovirals) should be used.</p><p>The 100&nbsp;mg usual dose of lamivudine used for the treatment of HBV is not appropriate for patients who acquire HIV or are co‑infected with HBV and HIV. If a patient with unrecognised or untreated HIV infection is prescribed the dose of lamivudine recommended for the treatment of HBV, rapid emergence of HIV resistance and a limitation of treatment options is likely to result because of the subtherapeutic dose and the inappropriate use of monotherapy for HIV treatment. HIV counselling and testing should be offered to all patients before beginning treatment with lamivudine for HBV and periodically during treatment.</p><p>&nbsp;</p><p><u>Transmission of hepatitis B</u></p><p>There is no information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with lamivudine. The standard recommended procedures for hepatitis B virus immunisation in infants should be followed.</p><p>Patients should be advised that therapy with lamivudine has not been proven to reduce the risk of transmission of hepatitis B virus to others and therefore, appropriate precautions should still be taken.</p><p>&nbsp;</p><p><u>Interactions with other medicinal products</u></p><p>Zeffix should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).</p><p>The combination of lamivudine with cladribine is not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged substance.</p><p>&nbsp;</p><p>Lamivudine is predominantly eliminated by active organic cationic secretion. The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine.</p><p>&nbsp;</p><p>Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine.</p><p>Administration of trimethoprim/sulphamethoxazole 160&nbsp;mg/800&nbsp;mg increased lamivudine exposure by about 40&nbsp;%. Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary.</p><p>&nbsp;</p><p>A modest increase in C<sub>max</sub> (28&nbsp;%) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) was not significantly altered. Zidovudine had no effect on the pharmacokinetics of lamivudine (see section 5.2).</p><p>&nbsp;</p><p>Lamivudine has no pharmacokinetic interaction with alpha-interferon when the two medicinal products are concurrently administered. There were no observed clinically significant adverse interactions in patients taking lamivudine concurrently with commonly used immunosuppressant medicinal products (e.g. cyclosporin A). However, formal interaction studies have not been performed.</p><p>&nbsp;</p><p><em>Emtricitabine</em></p><p>Due to similarities, Zeffix should not be administered concomitantly with other cytidine analogues, such as emtricitabine. Moreover, Zeffix should not be taken with any other medicinal products containing lamivudine (see section 4.4).</p><p>&nbsp;</p><p><em>Cladribine</em></p><p><em>In vitro</em> lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine. Therefore, the concomitant use of lamivudine with cladribine is not recommended (see section 4.4).</p><p>&nbsp;</p><p><em>Sorbitol</em></p><p>Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC<sub>&yen;</sub>) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. When possible, avoid chronic co-administration of Zeffix with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HBV viral load when chronic co-administration cannot be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section 5.3). Placental transfer of lamivudine has been shown to occur in humans.</p><p>&nbsp;</p><p>Available human data from the Antiretroviral Pregnancy Registry reporting more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect. Less than 1% of these women have been treated for HBV, whereas the majority was treated for HIV at higher doses and with other concomitant medications. Zeffix can be used during pregnancy if clinically needed.<u> </u></p><p>&nbsp;</p><p>For patients who are being treated with lamivudine and subsequently become pregnant consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (less than 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age.&nbsp; The total amount of lamivudine ingested by a breastfed infant is very low and is therefore likely to result in exposures exerting a sub-optimal antiviral effect.&nbsp; Maternal hepatitis B is not a contraindication to breast-feeding if the new born is adequately managed for hepatitis B prevention at birth, and there is no evidence that the low concentration of lamivudine in human milk leads to adverse reactions in breastfed infants.&nbsp; Therefore, breastfeeding may be considered in breast-feeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.&nbsp; Where there is maternal transmission of HBV, despite adequate prophylaxis, consideration should be given to discontinuing breastfeeding to reduce the risk of the emergence of lamivudine resistant mutants in the infant.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Reproductive studies in animals have shown no effect on male or female fertility (see section 5.3).</p><p>&nbsp;</p><p><u>Mitochondrial dysfunction</u></p><p>Nucleoside and nucleotide analogues have been demonstrated <em>in vitro</em> and <em>in vivo</em> to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be informed that malaise and fatigue have been reported during treatment with lamivudine. The clinical status of the patient and the adverse reaction profile of lamivudine should be borne in mind when considering the patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients. The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions </u></p><p>Adverse reactions are listed below by system organ class and frequency. Frequency categories are only assigned to those adverse reactions considered to be at least possibly causally related to lamivudine. Frequencies are defined as: very common (&sup3;&nbsp;1/10), common (&sup3;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&sup3;&nbsp;1/1000 to &lt;&nbsp;1/100), rare (&sup3;&nbsp;1/10,000 to &lt;&nbsp;1/1000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available data).&nbsp;</p><p>&nbsp;</p><p>The frequency categories assigned to the adverse reactions are mainly based on experience from clinical trials including a total of 1,171 patients with chronic hepatitis B receiving lamivudine at 100mg.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Lactic acidosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong>:</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>ALT elevations (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Exacerbations of hepatitis, primarily detected by serum ALT elevations, have been reported &lsquo;on-treatment&rsquo; and following lamivudine withdrawal. Most events have been self-limited, however fatalities have been observed very rarely (see section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Elevations of CPK</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle disorders, including myalgia and cramps*</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p></td></tr></tbody></table><p>* In Phase III studies frequency observed in the lamivudine treatment group was not greater than observed in the placebo group</p><p><u>&nbsp;</u></p><p><u>Paediatric population </u></p><p>Based on limited data in children aged 2 to 17 years, there were no new safety issues identified compared to adults.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) have been reported. In patients with chronic hepatitis B there was no observed difference in incidence of these events between placebo and lamivudine treated patients.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>National Pharmacovigilance centre (NPC)</strong></p><ul><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: &nbsp;https://ade.sfda.gov.sa</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com</li><li>website: &nbsp;https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>For any information about this medicinal product, please contact</strong><strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com &nbsp;</li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific signs or symptoms have been identified following acute overdose with lamivudine, apart from those listed as adverse reactions.</p><p>&nbsp;</p><p>If overdose occurs the patient should be monitored and standard supportive treatment applied as required. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group - Antivirals for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors, ATC Code: J05AF05.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Lamivudine is an antiviral agent which is active against hepatitis B virus in all cell lines tested and in experimentally infected animals.</p><p>&nbsp;</p><p>Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound. The intracellular half-life of the triphosphate in hepatocytes is 17-19 hours <em>in vitro</em>. Lamivudine-TP acts as a substrate for the HBV viral polymerase.</p><p>&nbsp;</p><p>The formation of further viral DNA is blocked by incorporation of lamivudine-TP into the chain and subsequent chain termination.</p><p>&nbsp;</p><p>Lamivudine-TP does not interfere with normal cellular deoxynucleotide metabolism. It is also only a weak inhibitor of mammalian DNA polymerases alpha and beta. Furthermore, lamivudine-TP has little effect on mammalian cell DNA content.</p><p>&nbsp;</p><p>In assays relating to potential substance effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects. It has a very low potential to decrease mitochondrial DNA content, is not permanently incorporated into mitochondrial DNA, and does not act as an inhibitor of mitochondrial DNA polymerase gamma.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>Experience in patients with HBeAg positive CHB and compensated liver disease</em></p><p>In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication [34-57&nbsp;% of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD &lt; 1.6pg/ml)}, normalised ALT level (40-72&nbsp;% of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 16-18&nbsp;% of patients), improved histology (38-52&nbsp;% of patients had a &sup3; 2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17&nbsp;% of patients) and progression to cirrhosis.</p><p>&nbsp;</p><p>Continued lamivudine treatment for an additional 2 years in patients who had failed to achieve HBeAg seroconversion in the initial 1 year controlled studies resulted in further improvement in bridging fibrosis. In patients with YMDD mutant HBV, 41/82 (50&nbsp;%) patients had improvement in liver inflammation and 40/56 (71&nbsp;%) patients without YMDD mutant HBV had improvement. Improvement in bridging fibrosis occurred in 19/30 (63&nbsp;%) patients without YMDD mutant and 22/44 (50&nbsp;%) patients with the mutant. Five percent (3/56) of patients without the YMDD mutant and 13 % (11/82) of patients with YMDD mutant showed worsening in liver inflammation compared to pre-treatment.&nbsp; Progression to cirrhosis occurred in 4/68 (6&nbsp;%) patients with the YMDD mutant, whereas no patients without the mutant progressed to cirrhosis.</p><p>&nbsp;</p><p>In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48&nbsp;% (28/58) and 47&nbsp;% (15/32), respectively. HBeAg seroconversion was increased in patients with elevated ALT levels; 77&nbsp;% (20/26) of patients with pre-treatment ALT &gt; 2 x ULN seroconverted. At the end of 5 years, all patients had HBV DNA levels that were undetectable or lower than pre-treatment levels.</p><p>&nbsp;</p><p>Further results from the trial by YMDD mutant status are summarised in Table 2.</p><p>&nbsp;</p><p><strong>Table 2: Efficacy results 5 years by YMDD status (Asian Study) NUCB3018</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>&nbsp;</em></strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Subjects, % (no.)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>YMDD mutant</em></strong><strong> <em>HBV status</em></strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
  style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_99b44d1b-b9fd-4af7-b1b2-8256bb068089 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
  style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></i></b><![endif]--></p></td><td colspan="3" style="vertical-align:top"><p>YMDD<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>Non-YMDD<sup>1</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; <u>HBeAg seroconversion</u></strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><u><span style='mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_28fecbd0-1a0b-4baa-8b85-879ce113a73f \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></u></b><![endif]--><strong><u>&nbsp;</u></strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><u><span style='mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></u></b><![endif]--></p><p>&nbsp;</p><p>&nbsp;- All patients<!--[if supportFields]><span style='mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
  color:black;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_633ffee8-328a-4489-a25f-59f5ae5f939f \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman";color:black;mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;- Baseline ALT &pound;&nbsp;1&nbsp;x&nbsp;ULN<sup>2</sup></p><p>&nbsp;- Baseline ALT &gt;&nbsp;2&nbsp;x&nbsp;ULN</p><p>&nbsp;</p><p><strong>&nbsp; <u>Undetectable HBV DNA</u></strong></p><p>&nbsp;</p><p>&nbsp;- Baseline <sup>3</sup></p><p>&nbsp;</p><p>&nbsp;- Week 260 <sup>4</sup></p><p>&nbsp; negative</p><p>&nbsp; positive &lt; baseline</p><p>&nbsp; positive &gt; baseline</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp; <u>ALT</u><u> normalisation</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;- </strong>Baseline</p><p><strong>&nbsp; </strong>normal</p><p><strong>&nbsp; </strong>above normal</p><p>&nbsp;</p><p><strong>&nbsp;- </strong>Week 260</p><p><strong>&nbsp; </strong>normal</p><p>&nbsp; above normal &lt; baseline</p><p>&nbsp; above normal &gt; baseline</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>38</p><p>9</p><p>60</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>5</p><p>&nbsp;</p><p>&nbsp;</p><p>8</p><p>92</p><p>0</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>28</p><p>73</p><p>&nbsp;</p><p>&nbsp;</p><p>46</p><p>21</p><p>32</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>(15/40)</p><p>(1/11)</p><p>(9/15)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(2/40)</p><p>&nbsp;</p><p>&nbsp;</p><p>(2/25)</p><p>(23/25)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(11/40)</p><p>(29/40)</p><p>&nbsp;</p><p>&nbsp;</p><p>(13/28)</p><p>(6/28)</p><p>(9/28)</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>72</p><p>33</p><p>100</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>6</p><p>&nbsp;</p><p>&nbsp;</p><p>0</p><p>100</p><p>0</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>33</p><p>67</p><p>&nbsp;</p><p>&nbsp;</p><p>50</p><p>0</p><p>50</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>(13/18)</p><p>(2/6)</p><p>(11/11)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(1/18)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(4/4)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>(6/18)</p><p>(12/18)</p><p>&nbsp;</p><p>&nbsp;</p><p>(2/4)</p><p>&nbsp;</p><p>(2/4)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients designated as YMDD mutant were those with &sup3;5% YMDD mutant HBV at any annual time-point during the 5-year period. Patients categorised as non-YMDD mutant were those with &gt; 95% wild-type HBV at all annual time-points during the 5-year study period</p><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper limit of normal</p><p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abbott Genostics solution hybridisation assay (LLOD &lt; 1.6 pg/ml</p><p>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chiron Quantiplex assay (LLOD 0.7 Meq/ml)</p><p>&nbsp;</p><p>Comparative data according to YMDD status were also available for histological assessment but only up to three years. In patients with YMDD mutant HBV, 18/39 (46&nbsp;%) had improvements in necroinflammatory activity and 9/39 (23&nbsp;%) had worsening. In patients without the mutant, 20/27 (74&nbsp;%) had improvements in necroinflammatory activity and 2/27 (7&nbsp;%) had worsening.</p><p>&nbsp;</p><p>Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine. However, relapse following seroconversion can occur. In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39 % of the subjects. Therefore, following HBeAg seroconversion, patients should be periodically monitored to determine that serologic and clinical responses are being maintained. In patients who do not maintain a sustained serological response, consideration should be given to retreatment with either lamivudine or an alternative antiviral agent for resumption of clinical control of HBV.</p><p>&nbsp;</p><p>In patients followed for up to 16&nbsp;weeks after discontinuation of treatment at one year, post-treatment ALT elevations were observed more frequently in patients who had received lamivudine than in patients who had received placebo. A comparison of post-treatment ALT elevations between weeks 52 and 68 in patients who discontinued lamivudine at week 52 and patients in the same studies who received placebo throughout the treatment course is shown in Table&nbsp;3. The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.</p><p>&nbsp;</p><p><strong>Table 3: Post-treatment ALT Elevations in 2 Placebo‑Controlled Studies in Adults</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Patients with ALT Elevation/</p><p>Patients with Observations*</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal Value</p></td><td style="vertical-align:top"><p>Lamivudine</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>ALT &sup3;&nbsp;2&nbsp;x&nbsp;baseline value</p></td><td style="vertical-align:top"><p>37/137 (27&nbsp;%)</p></td><td style="vertical-align:top"><p>22/116 (19&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT &sup3;&nbsp;3&nbsp;x&nbsp;baseline value<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>29/137 (21&nbsp;%)</p></td><td style="vertical-align:top"><p>9/116 (8&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT &sup3;&nbsp;2&nbsp;x&nbsp;baseline value and absolute ALT &gt;&nbsp;500&nbsp;IU/l</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>21/137 (15&nbsp;%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8/116 (7&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT &sup3;2 x baseline value; and bilirubin &gt;2 x ULN and &sup3;2 x baseline value&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1/137 (0.7&nbsp;%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1/116 (0.9&nbsp;%)</p></td></tr></tbody></table><p>*Each patient may be represented in one or more category.</p><p><sup>&dagger;</sup>Comparable to a Grade 3 toxicity in accordance with modified WHO criteria.</p><p>ULN = Upper limit of normal.</p><p>&nbsp;</p><p><em>Experience in patients with HBeAg negative CHB</em></p><p>Initial data indicate the efficacy of lamivudine in patients with HBeAg negative CHB is similar to patients with HBeAg positive CHB, with 71&nbsp;% of patients having HBV DNA suppressed below the detection limit of the assay, 67&nbsp;% ALT normalisation and 38&nbsp;% with improvement in HAI after one year of treatment. When lamivudine was discontinued, the majority of patients (70&nbsp;%) had a return of viral replication. Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine. After two years of treatment in this study, ALT normalisation and undetectable HBV DNA occurred in 30/69 (43&nbsp;%) and 32/68 (47&nbsp;%) patients respectively and improvement in necroinflammatory score in 18/49 (37&nbsp;%) patients. In patients without YMDD mutant HBV, 14/22 (64&nbsp;%) showed improvement in necroinflammatory score and 1/22 (5&nbsp;%) patients worsened compared to pre-treatment.&nbsp; In patients with the mutant, 4/26 (15&nbsp;%) patients showed improvement in necroinflammatory score and 8/26 (31&nbsp;%) patients worsened compared to pre-treatment.&nbsp; No patients in either group progressed to cirrhosis.</p><p>&nbsp;</p><p><em>Frequency of emergence of YMDD mutant HBV and impact on the treatment response</em></p><p>Lamivudine monotherapy results in the selection of YMDD mutant HBV in approximately 24&nbsp;% of patients following one year of therapy, increasing to 69&nbsp;% following 5 years of therapy. Development of YMDD mutant HBV is associated with reduced treatment response in some patients, as evidenced by increased HBV DNA levels and ALT elevations from previous on-therapy levels, progression of signs and symptoms of hepatitis disease and/or worsening of hepatic necroinflammatory findings. Given the risk of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in patients with detectable serum HBV DNA at or beyond 24 weeks of treatment (see section 4.4).</p><p>&nbsp;</p><p>In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log<sub>10</sub>&nbsp;copies/ml compared to a median increase of 0.3 log<sub>10</sub>&nbsp;copies/ml in those patients receiving lamivudine monotherapy. Normalisation of ALT levels occurred in 31&nbsp;% (14/45) of patients receiving combined therapy versus 6&nbsp;% (3/47) receiving lamivudine alone. Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses.</p><p>&nbsp;</p><p>In a retrospective study to determine the factors associated with HBV DNA breakthrough, 159 Asian HBeAg-positive patients were treated with lamivudine and followed up for a median period of almost 30 months.&nbsp; Those with HBV DNA levels greater than 200 copies/mL at 6 months (24 weeks) of lamivudine therapy had a 60&nbsp;% chance of developing the YMDD mutant compared with 8&nbsp;% of those with HBV DNA levels less than 200&nbsp;copies/mL at 24 weeks of lamivudine therapy.&nbsp; The risk for developing YMDD mutant was 63% versus 13% with a cut off of 1000 copies/ml (NUCB3009 and NUCB3018).</p><p>&nbsp;</p><p><em>Experience in patients with decompensated liver disease</em></p><p>Placebo controlled studies have been regarded as inappropriate in patients with decompensated liver disease, and have not been undertaken. In non-controlled studies, where lamivudine was administered prior to and during transplantation, effective HBV DNA suppression and ALT normalisation was demonstrated. When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76&nbsp;&ndash;&nbsp;100&nbsp;%.</p><p><em>&nbsp;</em></p><p>As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD mutant HBV after 52 weeks treatment was higher (36&nbsp;%&nbsp;-&nbsp;64&nbsp;%) in the liver transplant population than in the immunocompetent CHB patients (14&nbsp;%&nbsp;-&nbsp;32&nbsp;%).</p><p>&nbsp;</p><p>Forty patients (HBeAg negative or HBeAg positive) with either decompensated liver disease or recurrent HBV following liver transplantation and YMDD mutant were enrolled into an open label arm of study NUC20904. Addition of 10&nbsp;mg adefovir dipivoxil once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV&nbsp;DNA of 4.6&nbsp;log<sub>10</sub>&nbsp;copies/ml. Improvement in liver function was also seen after one year of therapy. This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit.</p><p>&nbsp;</p><p><em>Experience in CHB patients with advanced fibrosis or cirrhosis</em></p><p>In a placebo-controlled study in 651 patients with clinically compensated chronic hepatitis B and histologically confirmed fibrosis or cirrhosis, lamivudine treatment (median duration 32 months) significantly reduced the rate of overall disease progression (34/436, 7.8&nbsp;% for lamivudine versus 38/215, 17.7&nbsp;% for placebo, p=0.001), demonstrated by a significant reduction in the proportion of patients having increased Child-Pugh scores (15/436, 3.4&nbsp;% versus 19/215, 8.8&nbsp;%, p=0.023) or developing hepatocellular carcinoma (17/436, 3.9&nbsp;% versus 16/215, 7.4&nbsp;%, p=0.047). The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA (23/209, 11&nbsp;%) compared to those without detectable YMDD mutant HBV (11/221, 5&nbsp;%). However, disease progression in YMDD subjects in the lamivudine group was lower than the disease progression in the placebo group (23/209, 11&nbsp;% versus 38/214, 18&nbsp;% respectively). Confirmed HBeAg seroconversion occurred in 47&nbsp;% (118/252) of subjects treated with lamivudine and 93&nbsp;% (320/345) of subjects receiving lamivudine became HBV DNA negative (VERSANT [version 1], bDNA assay, LLOD &lt; 0.7 MEq/ml) during the study.</p><p><em>&nbsp;</em></p><p><em>Experience in children and adolescents</em></p><p>Lamivudine has been administered to children and adolescents with compensated CHB in a placebo controlled study of 286 patients aged 2 to 17 years. This population primarily consisted of children with minimal hepatitis B. A dose of 3&nbsp;mg/kg once daily (up to a maximum of 100&nbsp;mg daily) was used in children aged 2 to 11 years and a dose of 100&nbsp;mg once daily in adolescents aged 12 years and above. This dose needs to be further substantiated. The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13&nbsp;% (12/95) for placebo versus 22&nbsp;% (42/191) for lamivudine; p=0.057).&nbsp; The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19&nbsp;% at week 52 up to 45&nbsp;% in patients treated continuously for 24 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85&nbsp;%. Following oral administration, the mean time (T<sub>max</sub>) to maximal serum concentrations (C<sub>max</sub>) is about an hour. At therapeutic dose levels i.e.</p><p>100&nbsp;mg once daily, C<sub>max</sub> is in the order of 1.1-1.5&nbsp;&micro;g/ml and trough levels were 0.015-0.020&nbsp;&micro;g/ml.</p><p>Co-administration of lamivudine with food resulted in a delay of T<sub>max</sub> and a lower C<sub>max</sub> (decreased by up to 47&nbsp;%). However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>From intravenous studies the mean volume of distribution is 1.3&nbsp;l/kg. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays low plasma protein binding to albumin.</p><p>Limited data shows lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF). The mean lamivudine CSF/serum concentration ratio 2-4&nbsp;hours after oral administration was approximately 0.12.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Lamivudine is predominately cleared by renal excretion of unchanged substance. The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10&nbsp;%) extent of hepatic metabolism and the low plasma protein binding.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean systemic clearance of lamivudine is approximately 0.3&nbsp;l/h/kg. The observed half-life of elimination is 18&nbsp;to19&nbsp;hours. The majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system). Renal clearance accounts for about 70&nbsp;% of lamivudine elimination.</p><p><strong>&nbsp;</strong></p><p><u>Special populations</u></p><p>Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. Dose reduction in patients with a creatinine clearance of &lt;&nbsp;50&nbsp;ml/min is necessary (see section 4.2).</p><p>The pharmacokinetics of lamivudine are unaffected by hepatic impairment. Limited data in patients undergoing liver transplantation show that impairment of hepatic function does not impact significantly on the pharmacokinetics of lamivudine unless accompanied by renal dysfunction.</p><p>In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of &lt;&nbsp;50&nbsp;ml/min (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity. At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reduction in liver weights. Reduction of erythrocytes and neutrophil counts were identified as the effects most likely to be of clinical relevance. These events were seen infrequently in clinical studies.</p><p>&nbsp;</p><p>Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues showed activity in an <em>in vitro</em> cytogenetic assay and the mouse lymphoma assay. Lamivudine was not genotoxic <em>in vivo</em> at doses that gave plasma concentrations around 60-70 times higher than the anticipated clinical plasma levels. As the <em>in vitro</em> mutagenic activity of lamivudine could not be confirmed by <em>in vivo</em> tests, it is concluded that lamivudine should not represent a genotoxic hazard to patients undergoing treatment.</p><p>&nbsp;</p><p>Reproductive studies in animals have not shown evidence of teratogenicity and showed no effect on male or female fertility. Lamivudine induces early embryolethality when administered to pregnant rabbits at exposure levels comparable to those achieved in man, but not in the rat even at very high systemic exposures.</p><p>&nbsp;</p><p>The results of long term carcinogenicity studies with lamivudine in rats and mice did not shown any carcinogenic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>Microcrystalline cellulose&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Sodium starch glycolate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Magnesium stearate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Tablet film coat</u></p><p>Hypromellose</p><p>Titanium dioxide</p><p>Macrogol 400</p><p>Polysorbate 80</p><p>Synthetic yellow and red iron oxides</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Store below 30<!--[if supportFields]><span
style='mso-element:field-begin'></span>SYMBOL 176\u<![endif]--><!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]-->C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Double foil blisters, laminated with polyvinyl chloride.</p><p>&nbsp;</p><p>Not all pack-sizes may be marketed.</p><p>&nbsp;</p><p><em>ZEFFIX </em>is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy; 2024 GSK group of companies. All rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Delpharm Poznań Spółka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland

Packed by: 
Glaxo Saudi Arabia Ltd.*, Jeddah, Saudi Arabia

Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.*, Jeddah, Saudi Arabia
*member of the GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version Number: UK_v17
Date of Revision of the Text: 21 June 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>